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ABSTRACT 
The purpose o f  t h i s  work, i s  t o  develop radioimmune assays (RIA) and 
enzyme-linked immune assays f o r  measurement o f  pro-urokinase and t h e  two a c t i v e  
forms o f  t h e  enzyme. Po lyc lona l  and monoclonal an t ibod ies ,  w i t h  d e s i r e d  
s p e c i f i c i t i e s  aga ins t  p rese lec ted  s y n t h e t i c  reg ions  o f  urok inase (UK), were 
obta ined by immunization w i t h  t h e  r e s p e c t i v e  s y n t h e t i c  pept ides  and used t o  
develop R I A  f o r  zymogen and t h e  two a c t i v a t e d  forms o f  UK. 
INTRODUCTION 
Continuous f l o w  e l e c t r o p h o r e s i s  i n  m i c r o g r a v i t y  has been employed i n  t h e  
It i s  necessary, however, t o  separa t ion  o f  k idney  c e l l s  i n t o  subgroups (1 ) .  
determine whether t h e  separated c e l l s  r e t a i n  f u n c t i o n .  K idney-ce l l  subgroups 
produce v a r i o u s  amounts o f  UK. Present ly ,  t h e  assay f o r  UK depends on t h e  
measurement o f  enzymic a c t i v i t y .  T h i s  method i s  n o t  very  s e n s i t i v e  and i t  i s  an 
u n r e l i a b l e  i n d i c a t o r  o f  t h e  amount o f  secreted UK because o f  t h e  p r o d u c t i o n  o f  
enzyme i n h i b i t o r s  by t h e  c e l l s .  Furthermore, t h e  method i s  unable t o  d e t e c t  t h e  
zymogen, which i s  t h e  i n i t i a l  s y n t h e t i c  product. The zymogen i s  synthes ized as a 
s i n g l e  c h a i n  p r o t e i n  composed o f  411 amino a c i d  res idues  (2-4). 
cha in  zymogen has no enzymatic a c t i v i t y .  
cleavaqe o f  t h e  p e p t i d e  bond Lys.158-Ile.159 and t h e  l o s s  o f  Lys-158, t o  produce 
a two-chain h i g h  molecular  weiqht  a c t i v e  UK (3,4). I n  t h i s  a c t i v e  enzyme, t h e  A 
c h a i n  ( res idues  1-157) i s  l i n k e d  t o  t h e  B cha in  ( res idues  159-411) by a d i s u l f i d e  
bond between Cys-148 and Cys-279 (3,4). Cleavage o f  t h e  bond between Lys-135 and 
Lys-136 removes t h e  segment 1-135 and g ives  a low molecular  weight  a c t i v e  enzyme 
(5,6) i n  which p e p t i d e  136-157 (A1 c h a i n )  i s  l i n k e d  t o  t h e  B c h a i n  by t h e  above 
d i s u l f i d e  bond. Product ion by k idney-ce l l  subgroups o f  normal, o r  even high, 
l e v e l s  o f  UK cannot be measured when l i t t l e  o r  none o f  t h e  zymogen undergoes 
a c t i v a t i o n .  
c o r r e l a t i o n  w i t h  v i a b i l i t y  and a c t i v i t y  o f  t h e  var ious  c e l l  groups, a v e r y  
p r e c i s e  method f o r  measurement o f  a l l  o f  t h e  forms o f  urok inase ( i .e .  zymogen and 
t h e  two a c t i v e  forms)  i s  needed. 
radioimmune assays (RIA) and enzyme-1 inked immune assays f o r  measurement o f  t h e  
t h r e e  forms of t h e  enzyme. 
and monoclonal a n t i b o d i e s  w i t h  s p e c i f i c i t i e s  d i r e c t e d  aga ins t  p r e s e l e c t e d  reg ions  
of UK. These prese lec ted  reg ions  are  made s y n t h e t i c a l l y  a i d  t h e  s y n t h e t i c  
pept ides  are  .used as immunogens t o  o b t a i n  a n t i b o d i e s  o f  t h e  d e s i r e d  s p e c i f i c i t i e s  
(7-9). These a n t i b o d i e s  w i l l  be used t o  develop R I A  and ELISA assays f o r  zymogen 
and a c t i v a t e d  UK. 
It should be noted t h a t  development o f  these assays f o r  UK w i l l  have a u s e f u l  
c l i n i c a l  sp in -o f f .  The enzyme i s  secreted b y  human carcinomas, e s p e c i a l l y  in t h e  
lung, p ros ta te ,  b r e a s t  and co lon  cancers (10-13). 
assay f o r  UK, i t  w i l l  be p o s s i b l e  t o  d e t e c t  these cancers e a r l y ,  even b e f o r e  a 
s o l i d  tumor becomes v i s i b l e .  E a r l y  d e t e c t i o n  w i l l  be ext remely u s e f u l  f o r  des ign 
o f  therapy. 
Abbrev ia t ions :  UK, urokinase; R I A ,  radioimmune assay; BSA, bov ine serum albumin; 
PBS, 0.15 M NaC1 i n  0.01 M sodium phosphate b u f f e r ,  pH 7.2 
T h i s  s i n g l e  
A c t i v a t i o n  o f  t h e  zymogen i n v o l v e s  
I n  o r d e r  t o  b e t t e r  mon i to r  k idney  c e l l  separa t ion  and o b t a i n  a sound 
The purpose o f  t h i s  work i s  t o  develop 
These assays depend on t h e  p r e p a r a t i o n  o f  p o l y c l o n a l  
By developing a s e n s i t i v e  
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11 E THO D S 
Preparation of peptides and peptide conjugates 
Peptides were used as immunogens for the preparation of antibodies that 
possess pre-determined specificities. The locations of these regions within the 
UK polypeptide chain are shown in Table 1. These peptides were (or are being) 
synthesized, purified and analyzed by previously pub1 ished procedures (7-9). 
Synthetic peptides were coupled to exhaustively succinylated (Su) derivatives o f  
BSA, or hen lysozyme or to the native proteins after activation of the carrier 
carboxyl groups by conversion to the e-ni tropheny-1 ester groups (14). The extent 
of coupling was determined by amino acid analysis of acid hydrolysates of the 
peptide-protein conjugates. 
Antisera against peptides 
(a) Immunization by peptide-protein conjugates: Mice were injected and boosted 
with the peptide-SuBSA conjugate (50 pg per mouse) as an emulsion in complete 
Freund's adjuvant in the footpads and subcutaneously in the neck. 
bleedings from 10 days prior, up to 230 days after, the first injection will be 
collected and studied separately. (b) Immunization with free peptide: In view 
of the finding ( 7 )  that small synthetic peptides (6 residues or larger), when 
immunized in their free form in complete Freund's adjuvant, will stimulate an 
vivo antibody response, peptides were injected into mice in their free form (i.e. 
without coupling to carrier). 
as an emulsion in complete Freund's adjuvant distributed into three sites as 
above. The animals were boosted with similar doses 3 weeks after the first 
injection and thereafter monthly. Serial bleedings from 10 days before, up to 
200 days after, the initial injection were studied separately. 
Antibodies against the synthetic peptides were raised in mice by two methods 
Serial 
Each animal received peptide (25-50 pg per mouse) 
Preparation of monoclonal antibodies of preselected specificities 
The recent discovery ( 7 )  that synthetic peptides will evoke antibody forma- 
tion when used as immunogens in their free form (i.e. without coupling to a 
carrier) has been exploited in this laboratory to prepare monoclonal antibodies 
with preselected submolecular binding specificities to desired protein regions 
(15). Peptides representing antigenic sites as well as synthetic peptides 
representing surface regions that are not antigenic when the whole molecule is 
used as an immunogen have been shown to produce antisera and subsequently 
monoclonal antibodies of preselected specificities (16,17). 
Mice were immunized a s  above with a given synthetic peptide (25-50 pg) in 
complete Freund's adjuvant and boosted and test-bled at 3 week intervals until 
hiqh antibody titer was obtained in the test sera. Somatic cell fusions, 
hybridoma selection, limiting dilution cloning and subcloning, and hybrid cell 
expansion were performed as described by Schmitz et al. (15). Expanded subclones 
were also injected into BALB/cByJ mice ( 2  x 106 cXls/l.O ml fresh tissue 
culture media) that had been primed with pristane (Sigma Chemical Co., St. Louis, 
MO). Ascites fluid were collected, clarified and stored frozen at -2OOC until 
screened for the presence of hybridoma antibodies. 
Radio1 abell ing of proteins 
Corp., Arlington Heights, IL) using the chloramine-T method (18). 
was separated from the radiolabelled sample by gel filtration on Sephadex 6-25 
(Pharmacia Fine Chemicals, Piscataway, NJ). 
assayed by precipitation with 10% (v/v) trichloracetic acid. 
Immune IgG preparations or protein A were radiolabelled with 1251 (Amersham 
Unbound 1251 




Syn the t ic  pept ides represent ing  d i f f e r e n t  reg ions  o f  human urokinase* 
Peptides f rom the  reg ion  1-135 ( t o  make an t ibod ies  s p e c i f i c  f o r  t h i s  reg ion )  
Pep t i de 
(1 )  1-12 
( 2 )  59-73 
( 3 )  102-111 













103 I 1 1 3  
R.N.P.D.N.R.R.R.P.W.C 
102 112 
G a t  131) [126 135 
(8) (102-112)-( 126-135) C.R.N.P.D.N.R.R.R.P 
~.M.v.H.D.G.A.D - .G.K 
B. Peptides s p e c i f i c  f o r  t he  zymogen ( t o  make an t ibod ies  s p e c i f i c  f o r  t h e  s i n g l e  
cha in  zymogen). 
( 9 )  155-162 P.R.F.K.I.1.G 
(10) 154-163 R.P.R.F.K.I.1.G.G.E 
C. Peptides from the  B cha in  ( t o  make an t ibod ies  t h a t  w i l l  r e a c t  w i t h  a l l  forms 
o f  t he  enzyme). 
(11 )  177-189 Y.R.R.H.R.G.G.S.V.T.Y.V.C 
(12) 205-215 C.F.1.D.Y.P.K.K.E.D.Y 
(13 )  222-233 S.R.L.N.S.N.T.Q.G.E.M.K 
(14) 319-341 L.1.S.H.R.E.C.Q.Q.P.H.Y.Y.G 
I ‘S 
(15)  282-293 
(16 )  401-411 
(17) (177-189) 








The s i n g l e  l e t t e r  no ta t i ons  o f  t h e  amino ac ids  are: A, a lan ine;  C, cys te ine ;  
D, aspa r t i c  ac id ;  E, g lu tamic ac id ;  F, phenyla lan ine;  G, g l yc ine ;  H, h i s t i d i n e ;  I ,  
i so leuc ine ;  K, l y s i n e ;  L, leuc ine,  M, methionine; N, asparagine; P, p r o l i n e ;  Q, 
glutamine; R, a rg in ine ;  S, serine; T, threonine;  V, va l i ne ;  W ,  t ryptophan;  Y, 
t y ros ine .  From r e f .  52. 
* 
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Screening f o r  an t ibody  b i n d i n g  by p l a t e  assa 
P o l v v i n v l c h l o r i d e  p r o t e i n  assay p l a t e s  (:ostar, Cambridqe, MD) were incubated 
f o r  3 hours -a t  37OC w i t h  excess ( l i 5  pg i n  50 ug o f  PBS/weli) t e s t  and c o n t r o l  
antigens, washed e x t e n s i v e l y  w i t h  PBS, and b locked w i t h  1% BSA i n  PBS 
( 1 0 0 v l / w e l l )  f o r  1 h r  a t  37OC t o  prevent  non-speci f ic  b i n d i n g  o f  subsequent 
reagents. A f t e r  washing, t h e  p l a t e s  were used f o r  b i n d i n g  antibody. 
anti-UK ant ibod ies  us ing  a s o l i d  phase R I A  descr ibed by Sakata and Atass i  (19)  as 
m o d i f i e d  by Schmitz e t  a l .  (15) .  
b i n d i n g  s p e c i f i c i t i e s  t o  pept ides.  B r i e f l y ,  R I A  p l a t e s  t h a t  had been coated w i t h  
t h e  appropr ia te  t e s t  ant igens ( v a r i o u s  forms of UK o r  pept ide  conjugates)  were 
incubated f o r  3 hours a t  37OC w i t h  an an t ibody  p r e p a r a t i o n  (50 p l / w e l l )  
a p p r o p r i a t e l y  p r e d i l u t e d  i n  PBS-BSA so as t o  maximize s p e c i f i c  b ind ing .  
p l a t e s  were subsequently washed w i t h  PBS and a m p l i f i e d  w i t h  excess (1:lOOO 
d i l u t i o n  o f  t h e  s tock reagent i n  PBS-BSA) r a b b i t  anti-mouse IgG + IgM a n t i s e r a  
( L i t t o n  B ionet ics ,  Kensington, MS) f o r  2 h r s  a t  37OC. 
p l a t e s  were developed w i t h  excess (2.0 x 105 cpm i n  50 p1 PBS-BSA/well) 1251- 
l a b e l l e d  p r o t e i n  A f o r  2 h r s  a t  room temperature, washed, and then separated 
i n t o  i n d i v i d u a l  w e l l s  t h a t  are counted i n  a gamma counter  (Beckman Inst ruments,  
Inc., I r v i n e ,  CA). Resu l ts  a re  c o r r e c t e d  f o r  n o n s p e c i f i c  (0.1-2%) b i n d i n g  
detected i n  c o n t r o l  w e l l s  no t  coated w i t h  t e s t  a n t i g e n  b u t  b locked w i t h  BSA. 
Sera, c u l t u r e  supernatants and c l a r i f i e d  a s c i t e s  f l u i d s  were screened f o r  
Th is  assay was a l s o  used t o  determine an t ibody  
The 
A f t e r  washing, t h e  
When peptide-SuBSA conjugates are  t h e  immunizing ant igens then an t ibody  
responses were analyzed by peptide-lysozyme ( n o t  s u c c i n y l  lysozyme) conjugates 
s ince  lysozyme and SuBSA do no t  cross-react  immunochemically. 
non-speci f ic  b i n d i n g  i s  der ived  f rom b i n d i n g  t o  lysozyme c o n t r o l .  When t h e  f r e e  
pept ides  were t h e  ant igens then a n t i b o d i e s  were analyzed on peptide-SuBSA 
conjugates and employing lysozyme and SuBSA as c o n t r o l s .  
C o r r e c t i o n  f o r  
RESULTS AND D I S C U S S I O N  
Ant ibod ies  t h a t  r e a c t  s p e c i f i c a l l y  w i t h  t h e  zymogen and t h e  a c t i v e  form t h a t  has 
an A cha in  ( res idues  1-157) and a B c h a i n  ( res idues  159-411) 
These w i l l  be a n t i b o d i e s  t h a t  r e a c t  s p e c i f i c a l l y  w i t h  t h e  r e g i o n  1-135 o f  t h e  
A chain.  
b a s i s  o f  t h e  p r e d i c t i o n  t h a t  t h e y  have a h i g h  p r o b a b i l i t y  t o  be on t h e  sur face.  
I n  o rder  f o r  an an t ibody  t o  b i n d  t o  a p r o t e i n ,  t h e  r e g i o n s  i t  recognizes must be 
on t h e  sur face  o f  t h e  p r o t e i n  (20-22). However, s ince  these p r e d i c t i v e  methods 
are n o t  e n t i r e l y  r e l i a b l e ,  severa l  areas (pept ides  1-8, Table 1)  were s e l e c t e d  
f o r  syn thes is  i n  o rder  t o  improve our  chances o f  success ( i .e .  o b t a i n i n g  
an t i -pept ide  a n t i b o d i e s  t h a t  w i l l  r e a c t  w i t h  t h e  whole molecule) .  These p e p t i d e s  
have a l l  been synthesized, p u r i f i e d  and c h a r a c t e r i z e d  and are  now being immunized 
i n t o  mice i n . o r d e r  t o  prepare p o l y c l o n a l  and monoclonal a n t i b o d i e s  t h a t  possess 
t h e  d e s i r e d  s p e c f i c i t i e s .  
C e r t a i n  r e g i o n s  o f  t h e  molecule were se lec ted  f o r  syn thes is  on t h e  
Ant ibod ies  t h a t  d i s t i n g u i s h  t h e  zymogen f rom t h e  a c t i v e  forms 
The convers ion  o f  t h e  zymogen t o  t h e  a c t i v e  enzyme, i n v o l v e s  s c i s s i o n  a t  
Lysine-158. 
ou t  t h r e e  res idues  i n  each d i r e c t i o n  ( p e p t i d e  9, Table 1) .  A lso  another  p e p t i d e  
was made, e l o n g a t i n g  f o u r  and f i v e  res idues  on t h e  two s ides  o f  Lys-158 ( p e p t i d e  
10, Table 1). 
i n t a c t  p e p t i d e  w i l l  be expected t o  r e a c t  o n l y  w i t h  t h e  zymogen ( i n  which t h e  bond 
158-159 i s  i n t a c t )  and n o t  w i t h  t h e  a c t i v e  forms ( i n  which t h i s  bond c leaved and 
Lys-158 i s  l o s t ) .  
We have synthes ized a p e p t i d e  centered around Lysine-158, f a n n i n g  
These pept ides  were used as immunogens. Ant ibod ies  a g a i n s t  t h e  
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A f t e r  i n j e c t i o n  o f  t h e  pept ides  i n t o  outbred mice, and f u s i o n  o f  t h e i r  spleen 
c e l l s ,  17 monoclonal a n t i b o d i e s  were s e l e c t e d  f o r  t h e i r  s p e c i f i c i t y  t o  one of t h e  
pept ides  (154-163). Table 2 shows t h e  r e s u l t s  o f  t h i s  screening. These 
monoclonals were t e s t e d  f o r  b i n d i n g  t o  t h e  d i f f e r e n t  forms o f  UK by t h e  western 
b l o t  method. The n i t r o c e l l u l o s e  paper was incubated w i t h  c e l l  c u l t u r e  
supernatants f o l l o w e d  by 1251- label led r a b b i t  anti-mouse IgG. 
monoclonals showed s p e c i f i c  b i n d i n g  t o  s i n g l e  c h a i n  UK. 
now being expanded and t h e  monoclonal a n t i b o d i e s  p u r i f i e d  f o r  f u r t h e r  
c h a r a c t e r i z a t i o n  and t e s t i n g .  
Table 2. T i t e r  o f  monoclonal an t ibod ies  prepared by immunization w i t h  pept ides  
153-162 and 154-163. 
Three of t h e  



















Ant ibod ies  bound ( cpm) by 























































note: group A; mice were immunized w i t h  f r e e  p e p t i d e  153-162 
group C; mice were immunized w i t h  f r e e  p e p t i d e  154-163 
group D; mice were immunized w i t h  BSA-conjugated p e p t i d e  154-163 
Ant ibod ies  s p e c i f i c  f o r  t h e  B c h a i n  
t h e  enzyme. Several areas (pept ides  11-17, Table 1) were se lec ted  f rom t h e  B c h a i n  
on t h e  bas is  t h a t  t h e y  would have a h i g h  p r o b a b i l i t y  o f  be ing on t h e  surface. 
These pept ides  have been ( o r  a re  be ing)  synthesized, p u r i f i e d  and charac ter ized .  
Po lyc lona l  and monoclonal a n t i b o d i e s  aga ins t  these pept ides  should r e a c t  w i t h  t h e  
immunizing p e p t i d e s  and w i t h  a l l  forms o f  urokinase. 
As p a r t  o f  t h i s  work, we have a l s o  c a r r i e d  o u t  s t u d i e s  designed t o  determine 
optimum c u l t u r e  cond i t ions ,  f o r  k idney  c e l l s  i n  b i o r e a c t o r  and a l s o  t o  f i n d  t h e  
n u t r i e n t  requi rements a f t e r  e l e c t r o p h o r e t i c  separa t ion  o f  these c e l l s .  
necessary t o  determine whether t h e  c e l l s  r e q u i r e  any s p e c i f i c  n u t r i e n t s  a f t e r  
f l i g h t  experiments r e l a t i v e  t o  earth-based d u p l i c a t e  c u l t u r e s  o f  t h e  same c e l l s .  
D e p l e t i o n  o f  c e r t a i n  n u t r i e n t s  would i n d i c a t e  t h e  need f o r  a p p r o p r i a t e  
m o d i f i c a t i o n s  i n  c u l t u r e  media composi t ion f o r  b e t t e r  support o f  c e l l  growth and 
p r o l i f e r a t i o n  i n  f u t u r e  experiments. 
These w i l l  c o n s t i t u t e  general purpose a n t i b o d i e s  t h a t  r e a c t  w i t h  a l l  forms o f  
It i s  a l s o  
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OTHER S T U D I E S  
Us ing  h i g h  p r e s s u r e  l i q u i d  chromatography  (HPLC) and amino a c i d  a n a l y s i s ,  we 
have ana lyzed  164 samples o f  c u l t u r e  media t h a t  were s u p p l i e d  t o  us by JSC. The 
r e s u l t s  have been d e l i v e r e d  t o  NASA (JSC) and a computer  a n a l y s i s  o f  t h e  d a t a  i s  
now b e i n g  c a r r i e d  o u t  by  NASA s c i e n t i s t s .  
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